David Redfern - GSK Plc Chief Strategy Officer

GLAXF Stock  USD 18.84  0.14  0.74%   

Executive

Mr. David Redfern is Chief Strategy Officer of GlaxoSmithKline PLC. David joined the CET as Chief Strategy Officer in 2008 and is responsible for corporate development and strategic planning. Previously, he was Senior Vice President, Northern Europe with responsibility for GSKs pharmaceutical businesses in that region and, prior to that, he was Senior Vice President for Central and Eastern Europe. He joined GSK in 1994. David was appointed Chairman of the Board of ViiV Healthcare Limited in 2011 and a NonExecutive Director of the Aspen Pharmacare Holdings Limited Board in 2015. He has a BS degree from Bristol University and is a Chartered Accountant. since 2008.
Age 57
Tenure 17 years
Phone44 20 8047 5000
Webhttps://www.gsk.com

GSK Plc Management Efficiency

The company has return on total asset (ROA) of 0.0659 % which means that it generated a profit of $0.0659 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3131 %, meaning that it generated $0.3131 on every $100 dollars invested by stockholders. GSK Plc's management efficiency ratios could be used to measure how well GSK Plc manages its routine affairs as well as how well it operates its assets and liabilities.
GSK plc has accumulated 19.76 B in total debt with debt to equity ratio (D/E) of 0.98, which is about average as compared to similar companies. GSK plc has a current ratio of 1.4, which is within standard range for the sector. Debt can assist GSK Plc until it has trouble settling it off, either with new capital or with free cash flow. So, GSK Plc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like GSK plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for GSK to invest in growth at high rates of return. When we think about GSK Plc's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

EXECUTIVE Age

Steffen LangNovartis AG ADR
58
Charlotte PamerWieserNovartis AG ADR
N/A
David MDAmgen Inc
62
Lluis GomezGrifols SA ADR
42
Shannon KlingerNovartis AG ADR
49
Arvind SoodAmgen Inc
N/A
Pr BelvisiAstraZeneca PLC ADR
N/A
Giovanni MDBristol Myers Squibb
59
Cristina WilburRoche Holding AG
56
Matthew BuschAmgen Inc
50
Steffen LangNovartis AG
56
Ruth MarchAstraZeneca PLC ADR
N/A
Jerry MurryAmgen Inc
N/A
Linda HigginsGilead Sciences
63
Vasant NarasimhanNovartis AG
47
Cristina WilburRoche Holding AG
56
William WintersNovartis AG ADR
60
Joseph EidenBristol Myers Squibb
76
Etienne JousseaumeNovartis AG ADR
N/A
Werner BaumannBayer AG
61
Charles SawyersNovartis AG ADR
62
GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. Glaxosmithkline Plc is traded on OTC Exchange in the United States. GSK plc [GLAXF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

GSK plc Leadership Team

Elected by the shareholders, the GSK Plc's board of directors comprises two types of representatives: GSK Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GSK. The board's role is to monitor GSK Plc's management team and ensure that shareholders' interests are well served. GSK Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GSK Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
David Redfern, Chief Strategy Officer
Diana Conrad, Chief Officer
Emma Walmsley, President - Consumer Healthcare Worldwide
Sally Jackson, VP Office
Iain Mackay, CFO - Designate, Executive Director
James Ford, Senior Vice President General Counsel
Shobie Ramakrishnan, Chief Officer
Sarah EltonFarr, Head Relations
Julie Brown, Chief Officer
Tony Wood, Chief Officer

GSK Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is GSK Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

Other Information on Investing in GSK Pink Sheet

GSK Plc financial ratios help investors to determine whether GSK Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in GSK with respect to the benefits of owning GSK Plc security.